Sodium-glucosecotransporter type 2 (SGLT2) inhibitors are novel drugs that are widely used dueto their strong benefit in preventing hospitalization for decompensated heartfailure and renal protection, limiting the deterioration of the glomerularfiltration rate, independently of the presence of diabetes mellitus. The gene discussed is SLC5A2; the disease is diabetes mellitus.